Table 4

Summary of previous randomised controlled studies investigating the effects of adjuvant anti-VEGF on success following trabeculectomy with MMC

StudyAnti-VEGF agentLocation of administrationFollow-up time (months)Treatment group (n)Events (% of total)Complete success
(% of total)
TreatmentControlTreatmentControlTreatmentControl
Kahook, M.Y.Ranibizumab
(Lucentis)
Intravitreal6550 (0%)0 (0%)100%100%
Vanderwalle, E. et al Bevacizumab
(Avastin)
Intracameral1232348 (25%)16 (47%)75%
(71%)
53%
(51%)
Saeed, A.M. et al Bevacizumab
(Avastin)
Subconjunctival2413133 (23%)5 (38%)77%54%
Kiddee, W. et al Bevacizumab
(Avastin)
Subconjunctival1220199 (45%)8 (42%)55%58%
  • MMC, mitomycin-C; VEGF, vascular endothelial growth factor.